The purpose of this report was to analyse the efficacy and safety data of Stereotactic Body Radiation Therapy (SBRT) in patients with inoperable primary (hepatocellular carcinoma (HCC) and metastatic liver tumours (LM), to define the indications and the place of SBRT in the therapeutic strategy with the aim of its inclusion in the CCAM (French National list of reimbursement)
See also
HAS opinions and decisions
10/10/2016
HAS opinions and decisions
10/10/2016
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
KGYdrSaqKmfnR57M